(V3V) VITA 34 - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A0BL849
V3V: Stem Cells, Umbilical Cord Blood, Tissue, Genetic Tests, Viral Vectors
VITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany. Web URL: https://www.vita34.de
Additional Sources for V3V Stock
V3V Stock Overview
| Market Cap in USD | 74m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception |
V3V Stock Ratings
| Growth 5y | -91.6% |
| Fundamental | 62.0% |
| Dividend | 11.7% |
| Rel. Strength Industry | -736 |
| Analysts | - |
| Fair Price Momentum | 3.19 EUR |
| Fair Price DCF | 12.69 EUR |
V3V Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 39.0% |
V3V Growth Ratios
| Growth Correlation 3m | -40.7% |
| Growth Correlation 12m | -75.8% |
| Growth Correlation 5y | -81.4% |
| CAGR 5y | -20.88% |
| CAGR/Mean DD 5y | -0.53 |
| Sharpe Ratio 12m | -0.39 |
| Alpha | -29.26 |
| Beta | 0.42 |
| Volatility | 26.35% |
| Current Volume | 0k |
| Average Volume 20d | 1.4k |
What is the price of V3V stocks?
As of January 22, 2025, the stock is trading at EUR 4.14 with a total of 1 shares traded.
Over the past week, the price has changed by +1.97%, over one month by +0.98%, over three months by -8.81% and over the past year by -21.29%.
As of January 22, 2025, the stock is trading at EUR 4.14 with a total of 1 shares traded.
Over the past week, the price has changed by +1.97%, over one month by +0.98%, over three months by -8.81% and over the past year by -21.29%.
Is VITA 34 a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, VITA 34 (XETRA:V3V) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 61.99 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of V3V as of January 2025 is 3.19. This means that V3V is currently overvalued and has a potential downside of -22.95%.
Yes, based on ValueRay Fundamental Analyses, VITA 34 (XETRA:V3V) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 61.99 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of V3V as of January 2025 is 3.19. This means that V3V is currently overvalued and has a potential downside of -22.95%.
Is V3V a buy, sell or hold?
VITA 34 has no consensus analysts rating.
VITA 34 has no consensus analysts rating.
What are the forecast for V3V stock price target?
According to ValueRays Forecast Model, V3V VITA 34 will be worth about 3.5 in January 2026. The stock is currently trading at 4.14. This means that the stock has a potential downside of -15.94%.
According to ValueRays Forecast Model, V3V VITA 34 will be worth about 3.5 in January 2026. The stock is currently trading at 4.14. This means that the stock has a potential downside of -15.94%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 6.3 | 52.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3.5 | -15.9% |